Anondita Medicare Ltd
Anondita Medicare Q3 FY26 investor presentation: Revenue & Margins
Q3 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Anondita Medicare Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Revenue from operations (Standalone) for H1 FY26: ₹4,765.06 lakh; H1 FY25: ₹2,497.06 lakh; YoY growth: 91% (Page 26) - Revenue from operations (Consolidated) for H1 FY26: ₹5,409.70 lakh; H1 FY25: ₹3,1 EBITDA (H1 FY26): ₹1,678.51 lakh (Standalone), up 216% YoY from ₹530.98 lakh in H1 FY25 - EBITDA Margin (H1 FY26): 35.23% (Standalone), up 452 bps YoY from 21.26% in H1 FY25 - Profit After
From Anondita Medicare Ltd's Q3 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Revenue from operations (Standalone) for H1 FY26: ₹4,765.06 lakh; H1 FY25: ₹2,497.06 lakh; YoY growth: 91% (Page 26)
- Revenue from operations (Consolidated) for H1 FY26: ₹5,409.70 lakh; H1 FY25: ₹3,140.50 lakh; YoY growth: 72% (Page 22)
- Volume: Installed production capacity was 869 million pieces per annum with 16 manufacturing lines under WIP; planned capacity expansion at Noida facility to add ~1,360 million pieces per annum (Page 11)
2 more points from Anondita Medicare Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Anondita Medicare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Noida Facility Expansion:
- Approved capacity expansion of ~1,360 million pieces per annum (additional unit).
- Existing installed capacity: 869 million pieces per annum, with 16 manufacturing lines under work-in-progress (WIP).
- Total projected capacity post-expansion: ~2,229 million pieces per annum.
- Project investment estimated at approximately ₹75 crore.
- Funding through internal accruals and debt.
- Focus on financial discipline and operational leverage.
- Manufacturing Lines:
- Currently 11 manufacturing lines operational.
- 16 new manufacturing lines under WIP to enhance production.
- Status and Timeline:
- Expansion ongoing with equipment and lines under WIP.
- Production capacity increased by 307 million pieces as of February 23, 2026.
- No explicit final completion timeline stated, but investment and progress active during FY25-FY26.
2 more points from Anondita Medicare Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Personal Products
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Anondita Medicare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Anondita Medicare Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Continue your research
What Anondita Medi.'s management said in earlier quarters
Others in Personal Products this season
- Cupid (Q3 FY26)
Q3 FY26 revenue from operations: ₹93.50 Cr, up 101.71% YoY (Page 9). Key concall takeaways from Cupid Ltd's Q3 FY26 earnings call — and how it ranks against…
- Honasa Consumer Ltd (Q3 FY26)
Company delivered highest-ever quarterly revenue with 21.7% growth, supported by 30% volume growth (UVG). Key concall takeaways from Honasa Consumer Ltd's Q3…
- Emami Ltd (Q3 FY26)
Significant investment in digital marketing, with digital spends at 50% of total media spends. Key concall takeaways from Emami Ltd's Q3 FY26 earnings call…
- Dabur India Ltd (Q3 FY26)
. Key concall takeaways from Dabur India Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
Arthneeti Pro · Annual
Anondita Medicare Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Anondita Medicare Ltd Q3 FY26 results?
Revenue from operations (Standalone) for H1 FY26: ₹4,765.06 lakh; H1 FY25: ₹2,497.06 lakh; YoY growth: 91% (Page 26) - Revenue from operations (Consolidated) for H1 FY26: ₹5,409.70 lakh; H1 FY25: ₹3,1 EBITDA (H1 FY26): ₹1,678.51 lakh (Standalone), up 216% YoY from ₹530.98 lakh in H1 FY25 - EBITDA Margin (H1 FY26): 35.23% (Standalone), up 452 bps YoY from 21.26% in H1 FY25 - Profit After
What is Anondita Medicare Ltd share price analysis?
Anondita Medicare Ltd currently shows a neutral. The stock trades at a P/E of 61.0 with a market cap of ₹2,041 Cr. Investors should review the full earnings analysis for detailed insights.
Is Anondita Medicare Ltd planning capital expenditure?
Noida Facility Expansion: - Approved capacity expansion of ~1,360 million pieces per annum (additional unit).
Keep Anondita Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.